Results 201 to 210 of about 1,006,126 (240)

The many faces of intraperitoneal chemotherapy

Surgical Oncology, 2022
Cytoreductive surgery and intraperitoneal chemotherapy may offer chance for cure for patients with peritoneal metastasis. Many variations emerged, causing uncertainty when choosing the most suitable variant. By reviewing variability encountered in the management of peritoneal metastasis, we aim to raise awareness about this issue and hopefully initiate
Hisham Abdel Mageed, Kurt Van Der Speeten, Paul Sugarbaker   +2 more
openaire   +3 more sources

Intraperitoneal Chemotherapy and Immunotherapy

1988
1. The predictive model is validated empirically; a kinetic advantage for i.p. administration of certain antineoplastic drugs exist. 2. The concentrations achieved in the peritoneum are orders of magnitude greater than those found in the plasma, so rate-limiting systemic toxicities may be avoided. 3.
B. E. Wolf, P. H. Sugarbaker
openaire   +3 more sources

Carrier solutions for intraperitoneal chemotherapy [PDF]

Surgical Oncology Clinics of North America, 2003
Two pharmacokinetic problems appear to limit the effectiveness of intraperitoneal therapy: poor tumor penetration and nonuniform intraperitoneal distribution by the drug-containing solution. A better understanding of the pharmacodynamics of carrier solutions for intraperitoneal chemotherapy may impact on both these problems.
Paul H. Sugarbaker, Faheez Mohamed
openaire   +2 more sources

Concepts in intraperitoneal chemotherapy

Seminars in Oncology Nursing, 1987
NTRAPERITONEAL (IP) chemotherapy is the administration of chemotherapeutic agents via a catheter into the peritoneal cavity. The chemotherapy is placed in a large volume of fluid, usually 2 L, and infused into the abdominal cavity where it remains for a specified amount of time; then it is usually drained back out the catheter.
openaire   +3 more sources

Hyperthermic Intraperitoneal Chemotherapy

Advances in Anesthesia, 2005
Cancer treatment frequently requires a multimodality approach, involving surgical resection(s), radiotherapy, and chemotherapy. Advanced surgical approaches allow for the combination of two of these, offering patients intraoperative radiotherapy with surgical resection or intraoperative chemotherapy targeted and limited to a particular body region. The
Thomas B. Dougherty, Alicia M. Kowalski
openaire   +2 more sources

Intraperitoneal Chemotherapy With Cisplatin and Melphalan

JNCI Journal of the National Cancer Institute, 1988
Cisplatin and melphalan given ip exert a synergistic therapeutic effect against ascitic P388 leukemia in mice and have different dose-limiting toxic effects as well as favorable pharmacokinetic characteristics in ip phase I studies. We gave a total of 98 courses of cisplatin (escalated from 40 to 120 mg/m2) and melphalan (escalated from 12 to 30 mg/m2)
Ghanem Atassi, Yvon Kenis, Claire Nouwijnck, Henri Bondue, Claude Finet, Jeffrey S. Abrams, Jean-Paul Sculier, Nadine Crespeigne, Jean Claude Pector, Martine Piccart, Pierre Dodion   +10 more
openaire   +3 more sources

Intraperitoneal chemotherapy for ovarian cancer

Current Opinion in Oncology, 2006
Intraperitoneal chemotherapy for ovarian cancer is based on sound pharmacological principles and is technically feasible. There is mounting evidence, bolstered by a recent randomized trial, that in certain patients, this route of delivery may be superior to traditional intravenous chemotherapy.
Chad A. Hamilton, Jonathan S. Berek
openaire   +3 more sources

Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.

Journal of Clinical Oncology, 2003
PURPOSE To confirm the findings from uncontrolled studies that aggressive cytoreduction in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) is superior to standard treatment in patients with peritoneal carcinomatosis of colorectal ...
V. Verwaal, S. van Ruth, E. de Bree, Gooike W van Sloothen, H. van Tinteren, H. Boot, F. Zoetmulder   +6 more
semanticscholar   +1 more source

Intraperitoneal chemotherapy for colorectal cancer

Journal of Surgical Oncology, 2001
AbstractThe peritoneal surface remains an important failure site for patients with colorectal cancer. Peritoneal metastases of colorectal cancer are at present considered equal to distant metastatic disease. Consequently, peritoneal carcinomatosis is treated with systemic chemotherapy and surgery only to palliate complications such as obstruction ...
Eelco de Bree, Frans A. N. Zoetmulder, Arjen J Witkamp   +2 more
openaire   +3 more sources

Intraperitoneal chemotherapy in ovarian cancer

Cancer Treatment Reviews, 2000
From a theoretical viewpoint, intraperitoneal therapy (IP) in patients with ovarian cancer, a malignancy which remains mainly confined to the peritoneal cavity, is logical. Over the past decades this approach has evolved into a therapeutic strategy for a selected group of patients.
Nanno Mulder, Phb Willemse, de Elisabeth G. E. Vries, LS Hofstra   +3 more
openaire   +3 more sources